Journal: Scientific Reports

Article Title: LOXL2 attenuates osteoarthritis through inactivating Integrin/FAK signaling

doi: 10.1038/s41598-021-96348-x

Figure Lengend Snippet: Decreased expression of LOXL2 was found in mechanical stress-mediated cartilage osteoarthritis. ( A ) Immunohistochemical analysis of LOXL2 expression (×100, ×400) and ( B ) quantification of it in chondrocytes from samples treated as indicated at 4 or 7 d after force application (n = 12). Chondrocytes expressing LOXL2 is denoted by arrows. ( C ) RT-qPCR analysis (n = 3) of LOXL2 expression in chondrocytes from samples treated as indicated. Error bars represent S.D. *P < 0.05 versus Con, **P < 0.01 versus Con.

Article Snippet: After applied for 24 or 96 h in the 4- or 7-day groups, human recombinant LOXL2 (rhLOXL2, R&D Systems, 2639-AO-010, USA, 0.44 μg, a 0.2 μm filtered solution in MES and NaCl) or LOXL2 antibody (anti-LOXL2, Santa Cruz, sc-48724, USA, 2 μg, a 100 μg/ml solution in PBS) were injected locally into the TMJ on one side, and a vehicle (dimethyl sulfoxide; Solarbio) was injected on the other side, as described previously.

Techniques: Expressing, Immunohistochemical staining, Quantitative RT-PCR

Journal: Scientific Reports

Article Title: LOXL2 attenuates osteoarthritis through inactivating Integrin/FAK signaling

doi: 10.1038/s41598-021-96348-x

Figure Lengend Snippet: LOXL2 alleviated mechanical force-mediated cartilage thinning. HE-stained cartilage sections were treated as indicated (n = 12). ( A ) Cartilage thinning in MF groups was recovered by rhLOXL2, ( B ) while worsened by anti-LOXL2. The scale bar indicates 100 μm. Cartilage thickness is indicated by a black bar. Quantification of cartilage thickness was listed below the HE-stained images (n = 12). *P < 0.05, **P < 0.01.

Article Snippet: After applied for 24 or 96 h in the 4- or 7-day groups, human recombinant LOXL2 (rhLOXL2, R&D Systems, 2639-AO-010, USA, 0.44 μg, a 0.2 μm filtered solution in MES and NaCl) or LOXL2 antibody (anti-LOXL2, Santa Cruz, sc-48724, USA, 2 μg, a 100 μg/ml solution in PBS) were injected locally into the TMJ on one side, and a vehicle (dimethyl sulfoxide; Solarbio) was injected on the other side, as described previously.

Techniques: Staining

Journal: Scientific Reports

Article Title: LOXL2 attenuates osteoarthritis through inactivating Integrin/FAK signaling

doi: 10.1038/s41598-021-96348-x

Figure Lengend Snippet: LOXL2 restored ECM degradation in mandibular condyle cartilage at 4 and 7 d after force application. Alcian blue-stained cartilage sections were treated as indicated (n = 12). ( A ) Degradation of proteoglycan in F groups was recovered by rhLOXL2, ( B ) while worsened by anti-LOXL2. Quantification was listed below (n = 12). *P < 0.05, **P < 0.01.

Article Snippet: After applied for 24 or 96 h in the 4- or 7-day groups, human recombinant LOXL2 (rhLOXL2, R&D Systems, 2639-AO-010, USA, 0.44 μg, a 0.2 μm filtered solution in MES and NaCl) or LOXL2 antibody (anti-LOXL2, Santa Cruz, sc-48724, USA, 2 μg, a 100 μg/ml solution in PBS) were injected locally into the TMJ on one side, and a vehicle (dimethyl sulfoxide; Solarbio) was injected on the other side, as described previously.

Techniques: Staining

Journal: Scientific Reports

Article Title: LOXL2 attenuates osteoarthritis through inactivating Integrin/FAK signaling

doi: 10.1038/s41598-021-96348-x

Figure Lengend Snippet: LOXL2 restored collagen II degradation in mandibular condyle cartilage at 4 and 7 d after force application. Immunohistochemical analysis of Collagen II expression and quantification of it in chondrocytes from samples treated as indicated (n = 12). ( A ) Degradation of collagen II in MF groups (4-days, p < 0.05; 7-days, p < 0.01; compared with the controls) was recovered by rhLOXL2(4-days, p < 0.05; 7-days, p < 0.01; compared with the MF groups), ( B ) while worsened by anti-LOXL2(4-days, p < 0.05; 7-days, p < 0.01; compared with the MF groups).

Article Snippet: After applied for 24 or 96 h in the 4- or 7-day groups, human recombinant LOXL2 (rhLOXL2, R&D Systems, 2639-AO-010, USA, 0.44 μg, a 0.2 μm filtered solution in MES and NaCl) or LOXL2 antibody (anti-LOXL2, Santa Cruz, sc-48724, USA, 2 μg, a 100 μg/ml solution in PBS) were injected locally into the TMJ on one side, and a vehicle (dimethyl sulfoxide; Solarbio) was injected on the other side, as described previously.

Techniques: Immunohistochemical staining, Expressing

Journal: Scientific Reports

Article Title: LOXL2 attenuates osteoarthritis through inactivating Integrin/FAK signaling

doi: 10.1038/s41598-021-96348-x

Figure Lengend Snippet: LOXL2 restored TNF-a over-expression in mandibular condyle cartilage at 4 and 7 d after force application. Immunohistochemical analysis of TNF-a expression and quantification of it in chondrocytes from samples treated as indicated at 4 or 7 d after force application (n = 12). ( A ) Degradation of TNF-a in MF groups (4-days, p < 0.05; 7-days, p < 0.01; compared with the controls) was recovered by rhLOXL2 (4-days, p < 0.05; 7-days, p < 0.01; compared with the MF groups), ( B ) while worsened by anti-LOXL2 (4-days, p < 0.05; 7-days, p < 0.01; compared with the MF groups).

Article Snippet: After applied for 24 or 96 h in the 4- or 7-day groups, human recombinant LOXL2 (rhLOXL2, R&D Systems, 2639-AO-010, USA, 0.44 μg, a 0.2 μm filtered solution in MES and NaCl) or LOXL2 antibody (anti-LOXL2, Santa Cruz, sc-48724, USA, 2 μg, a 100 μg/ml solution in PBS) were injected locally into the TMJ on one side, and a vehicle (dimethyl sulfoxide; Solarbio) was injected on the other side, as described previously.

Techniques: Over Expression, Immunohistochemical staining, Expressing

Journal: Scientific Reports

Article Title: LOXL2 attenuates osteoarthritis through inactivating Integrin/FAK signaling

doi: 10.1038/s41598-021-96348-x

Figure Lengend Snippet: LOXL2 restored IL-1β-mediated Collagen II degradation through Integrin/FAK pathway. ( A ) Flow chart of the isolation of TMJ chondrocytes and schematic diagram of agent-treated chondrocytes. ( B ) Western blot analysis and ( C ) quantitative results of LOXL2, Collagen II, Integrin β1, p-FAK and FAK expression in chondrocytes from samples treated as indicated. ( D ) RT-qPCR analysis of LOXL2, Collagen II, Integrin β1 and FAK expression in chondrocytes from samples treated as indicated. Error bars represent S.D. *P < 0.05, **P < 0.01.

Article Snippet: After applied for 24 or 96 h in the 4- or 7-day groups, human recombinant LOXL2 (rhLOXL2, R&D Systems, 2639-AO-010, USA, 0.44 μg, a 0.2 μm filtered solution in MES and NaCl) or LOXL2 antibody (anti-LOXL2, Santa Cruz, sc-48724, USA, 2 μg, a 100 μg/ml solution in PBS) were injected locally into the TMJ on one side, and a vehicle (dimethyl sulfoxide; Solarbio) was injected on the other side, as described previously.

Techniques: Isolation, Western Blot, Expressing, Quantitative RT-PCR